SCHEMBL6621873

SCHEMBL6621873

Oc1cc[c]c(C23CC4CC(CC(C4)C2)C3)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.43
GFER P55789 1/20 0.43
FAAH O00519 1/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
EPHX2 P34913 2/20 0.34
CNR2 P34972 2/20 0.34
MAPT P10636 4/20 0.33
XBP1 P17861 1/20 0.33
HSP90AA1 P07900 1/20 0.33
THRB P10828 2/20 0.33
USP2 O75604 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
RARA P10276 2/20 0.32
RARB P10826 2/20 0.32
RARG P13631 2/20 0.32
P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27636839 0.79 MEN1 (0.36) GAAMEN1KMT2APOLBGFER
SCHEMBL3893849 0.79 MEN1 (0.36) GAAMEN1KMT2APOLBGFER
SCHEMBL182120 0.72 ALDH1A1 (0.38) GAAMEN1KMT2APOLBGFER
SCHEMBL6622922 0.69 MEN1 (0.41) GAAMEN1KMT2APOLBGFER
SCHEMBL9170521 0.68 MEN1 (0.43) GAAMEN1KMT2APOLBGFER
SCHEMBL2420330 0.67 MEN1 (0.50) GAAMEN1KMT2APOLBGFER
SCHEMBL419753 0.67 MEN1 (0.59) GAAMEN1KMT2APOLBGFER
SCHEMBL3755595 0.67 MEN1 (0.55) GAAMEN1KMT2APOLBGFER
SCHEMBL24559531 0.65 LMNA (0.63) GAAMEN1KMT2APOLBGFER
SCHEMBL345588 0.65 LMNA (0.63) GAAMEN1KMT2APOLBGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463718-A1 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER Incyte San Diego Incorporated (US) 2004-10-06 EP disclosed
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer INCYTE SAN DIEGO INCORPORATED 2004-05-20 US disclosed
WO-2003050098-A1 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER INCYTE SAN DIEGO INCORPORATED (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer PTPA, PTPRC, PTPRCAP GAA 1045/4885MEN1 3865/4885KMT2A 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.